SCHEMBL6320795

SCHEMBL6320795

COC(=O)c1ccc(CC(C(=O)NS(=O)(=O)c2ccc(C(C)C)cc2)c2ccc3nsnc3c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 3/20 0.39
CYP2C9 P11712 4/20 0.39
CYP3A4 P08684 3/20 0.39
CYP2C19 P33261 3/20 0.39
CYP1A2 P05177 2/20 0.39
MAPK1 P28482 2/20 0.39
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
FLT1 P17948 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
POLB P06746 1/20 0.38
ITGB3 P05106 1/20 0.36
ITGAV P06756 1/20 0.36
AKR1C3 P42330 2/20 0.36
AKR1C2 P52895 2/20 0.36
CYP2D6 P10635 1/20 0.36
BCL2 P10415 1/20 0.35
EDNRB P24530 1/20 0.35
CA12 O43570 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8709876 0.92 BCL2 (0.42) CYP2C9CYP3A4CYP2C19CYP1A2ALDH1A1
SCHEMBL8705052 0.91 MEN1 (0.45) CYP2C9CYP3A4CYP2C19MAPK1ALDH1A1
SCHEMBL6322172 0.91 TDP1 (0.40) EDNRAALDH1A1TSHRITGB3ITGAV
SCHEMBL8707231 0.90 SLC7A5 (0.39) EDNRAITGB3ITGAV
SCHEMBL8712259 0.90 BMP1 (0.43) ALDH1A1POLBAKR1C3AKR1C2CA9
SCHEMBL8711325 0.89 EGFR (0.40) ITGB3ITGAVAKR1C3AKR1C2NPC1
SCHEMBL8710009 0.89 GAA (0.41) ALDH1A1ITGB3ITGAVEDNRBRAB9A
SCHEMBL8709961 0.88 ITGB3 (0.36) EDNRAALDH1A1ITGB3ITGAVAKR1C3
SCHEMBL8709051 0.86 MAPT (0.39) ALDH1A1TSHRPOLBITGB3ITGAV
SCHEMBL8709959 0.86 EDNRA (0.43) EDNRACYP2C9CYP3A4CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014769-A1 Use of endothelin receptor antogonists for the treatment of tumour diseases MERCK PATENT GMBH (DE) 2005-01-20 US claimed
US-20050014769-A1 Use of endothelin receptor antogonists for the treatment of tumour diseases MERCK PATENT GMBH (DE) 2005-01-20 US disclosed
WO-1998041515-A1 ENDOTHOLIN RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 1998-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014769-A1 Use of endothelin receptor antogonists for the treatment of tumour diseases EDNRA, EDNRB, ECE1 EDNRA 1/4885CYP2C9 4547/4885CYP3A4 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.